Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Three researchers at the Kennedy Institute have been awarded grants by Arthritis Research UK to continue the fight against various forms of arthritis.

Three researchers at the Kennedy Institute, NDORMS have been awarded grants by Arthritis Research UK to continue the fight against various forms of arthritis.

With around 10 million people from all ages living with arthritis in the UK, and no known cure for it (except for gout), research aimed at understanding the causes, preventions and development of new treatments for arthritis is essential.

The three projects now funded at the Kennedy will further the knowledge base on arthritis, as well as investigate potential new therapies for specific forms of the condition, namely osteoarthritis and rheumatoid arthritis.

 

Using CRISPR/Cas9 genome editing to identify therapeutic targets of microRNAs

MicroRNAs are small molecules key to gene expression – when information from a gene is used to make gene products, which go on to perform essential functions in the body. Problems with the regulation of microRNAs have been implicated in many diseases including arthritis. Current approaches to treatment look to modify the level of a specific microRNA; however, this is too high risk for clinical application as a single microRNA has multiple targets, some of which may be undesirable or harmful to alter. To overcome this obstacle, the new project now funded at the Kennedy will use the latest genome editing technology to alter individual microRNA target sites and determine their functional significance in human cells. In this way we will identify specific and relevant single sites for therapeutic targeting.

Lead researcher: Dr Chris Murphy.

 

Sulfation patterns of pericellular heparan sulfate regulate chondrocyte homeostasis: novel targets for OA therapy?

A successful cure for osteoarthritis can only be developed when we understand the detailed molecular changes that occur in the joints as the disease develops. We recently identified that a key cellular mechanism important for cartilage health is disrupted in osteoarthritis. We would like to use recently developed technologies to understand why this occurs, in order to be able to develop new drugs to treat or prevent this common and disabling joint disease.

Lead researcher: Dr Linda Troeberg.

 

IFN-lambda: novel biologics for controlling neutrophil-mediated pathology in rheumatic diseases?

Signaling molecules are responsible for transmitting information between cells in your body. Previous work by Professor Udalova’s group has recently discovered that a new signaling molecule - called interferon-lambda - better known for its role in the body’s response to viruses, can also stop and reverse the development of rheumatoid arthritis (RA). The research group believes this works by blocking the recruitment of white blood cells to the arthritic joint, where they usually increase the inflammation. The project now funded will investigate the roles of other cells and molecules in this process and ultimately translate our findings to clinical practice, using white blood cells from healthy donors and rheumatic patients (early RA and vasculitis.

Lead researcher: Professor Irina Udalova.

Similar stories

Immunology preprint reviews launched in Nature Reviews Immunology

Research

The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.

Drug may boost vaccine responses in older adults

General Research

A preliminary study shows that a drug which helps immune cells self-clean may improve vaccine protection in older adults

Living reviews launched by Oxford and Cardiff in the wake of COVID-19 research

Research

In a combined effort to help COVID-19 researchers the University of Oxford and Cardiff University have launched a series of “living reviews” in Oxford University Press’s new open access journal “Oxford Open Immunology”.

Oxford University awarded £2.4 million to fund DPhil research in inflammation, immunology and musculoskeletal disease

Awards Funding

Oxford University has today been awarded a £2.4 million grant, as part of the Kennedy Trust MB PhD scheme, to fund undergraduate medical students to undertake DPhil research in the areas of inflammation, immunology and musculoskeletal disease.

3D imaging reveals the role of blood vessels in hormone production

Research

New research from the Kusumbe Group at the Kennedy Institute has shown a direct correlation between age-related decline in capillary and artery numbers and hormone production in the endocrine system.

£3M invested to drive forward early translation through five new Oxford-Bristol Myers Squibb Fellowships

Awards General

Five new Oxford-Bristol Myers Squibb Fellowships representing an investment of £3M have been announced. The fellowships (formerly Oxford-Celgene) will support postdoctoral researchers and clinicians across five departments within the Medical Sciences Division and the Mathematical, Physical and Life Sciences Division, providing an opportunity for them to gain exposure to the field of commercial drug discovery and development.